NEUPERT PETER M 4

What Happened

• Peter Neupert, a director of Adaptive Biotechnologies Corp (ADPT), received an award of 15,625 shares on 2026-03-04. The filing reports an acquisition price of $0.00 (transaction code A), so the Form 4 lists the reported value as $0. This was a compensation-style grant/award — not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-04; Form 4 filed: 2026-03-06 (filed within the standard two-business-day window).
• Transaction type/code: Award/Grant (Code A).
• Shares involved: 15,625 shares; reported acquisition price: $0.00 (reported value $0).
• Shares owned after transaction: Not specified in the information provided.
• Footnotes/plan info: None provided in the excerpt; award may be subject to vesting or other restrictions (not detailed here).
• Timeliness: Filing date is 2026-03-06 for a 2026-03-04 transaction — appears to be timely.

Context

• Awards like this are typically compensation (e.g., restricted stock or RSUs) and often vest over time or are subject to restrictions; a $0 reported price on grant is common and does not reflect the market value of the shares. Such grants are routine for directors and do not alone indicate insider buying or selling intent.